AR080590A1 - Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2 - Google Patents
Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2Info
- Publication number
- AR080590A1 AR080590A1 ARP110100829A ARP110100829A AR080590A1 AR 080590 A1 AR080590 A1 AR 080590A1 AR P110100829 A ARP110100829 A AR P110100829A AR P110100829 A ARP110100829 A AR P110100829A AR 080590 A1 AR080590 A1 AR 080590A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- independently
- carboxy
- amino
- aryl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- -1 carboxy, cyano, hydroxy, amino Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- DWFIAIGURLKJHU-UHFFFAOYSA-N 2-[1-[2-methoxy-6-[2-[4-(trifluoromethoxy)phenyl]ethylamino]pyrimidin-4-yl]piperidin-3-yl]acetic acid Chemical compound C=1C(N2CC(CC(O)=O)CCC2)=NC(OC)=NC=1NCCC1=CC=C(OC(F)(F)F)C=C1 DWFIAIGURLKJHU-UHFFFAOYSA-N 0.000 abstract 1
- 206010012434 Dermatitis allergic Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Incluye también un método de tratamiento de un paciente mediante la administracion de una cantidad farmacéuticamente eficaz de un compuesto de este tipo, para enfermedades como alergias, asma bronquial, rinitis y dermatitis alérgica entre otras. Reivindicacion 1: Un compuesto de la formula (1) en el que m y n, independientemente uno de otro, se seleccionan de los numeros enteros 0, 1, 2 o 3; X e Y, independientemente uno de otro, se seleccionan a partir de CR1R2, NR1 u O, en los que X e Y no pueden ambos ser O; o X e Y, tomados juntos con el enlace entre ellos, forman un grupo fenilo opcionalmente sustituido por uno a cuatro grupos R3; cada Z, independientemente uno de otro, es CR1R2; R1, R2 y R3, independientemente uno de otro, se seleccionan del grupo constituido por H, halogeno, arilo, amino, alquilo opcionalmente sustituido, alcoxi opcionalmente sustituido, y carboxi; en los que alquilo opcionalmente sustituido puede ser sustituido por uno a tres del mismo o diferente halogeno, carboxi, ciano, hidroxi, amino o arilo; en los que alcoxi opcionalmente sustituido puede ser sustituido por uno a tres del mismo o diferente halogeno, carboxi, ciano, amino o arilo; en los que cada resto arilo, independientemente uno de otro, pueden ser opcionalmente sustituidos por hidroxi, amino, alquilo, alcoxi, carboxi o alcoxicarbonilo; con tal de que un halogeno no pueda ser ligado a un N; y con tal de que el compuesto no sea ácido (1-{2-metoxi-6-[2-(4-trifluorometoxi-fenil)-etilamino]-pirimidin-4-il}-piperidin-3-il)-acético; o un enantiomero del mismo, o un profármaco o sal del mismo farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31442810P | 2010-03-16 | 2010-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080590A1 true AR080590A1 (es) | 2012-04-18 |
Family
ID=43983955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100829A AR080590A1 (es) | 2010-03-16 | 2011-03-15 | Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130005728A1 (es) |
| EP (1) | EP2547672A1 (es) |
| JP (1) | JP2013522306A (es) |
| KR (1) | KR20130018770A (es) |
| CN (1) | CN103038228A (es) |
| AR (1) | AR080590A1 (es) |
| AU (1) | AU2011227417A1 (es) |
| BR (1) | BR112012023178A2 (es) |
| CA (1) | CA2793223A1 (es) |
| MX (1) | MX2012010035A (es) |
| RU (1) | RU2012143897A (es) |
| SG (1) | SG183533A1 (es) |
| TW (1) | TW201200133A (es) |
| UY (1) | UY33278A (es) |
| WO (1) | WO2011115940A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011137363A1 (en) * | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| WO2014066568A1 (en) | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| NZ729137A (en) | 2014-08-04 | 2022-07-29 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| CN105439964B (zh) * | 2015-12-09 | 2019-02-15 | 河北大学 | 一种阿伐那非中间体的制备方法 |
| DE102016216163B4 (de) * | 2016-08-29 | 2019-11-14 | Siemens Healthcare Gmbh | Verfahren zur Korrektur einer Signalphase bei der Aufnahme von Magnetresonanzsignalen, Magnetresonanzeinrichtung, Computerprogramm und Datenträger |
| KR20200109293A (ko) | 2017-09-13 | 2020-09-22 | 프로제너티, 인크. | 자간전증 바이오마커 및 관련된 시스템 및 방법 |
| SMT202200134T1 (it) | 2018-03-08 | 2022-05-12 | Incyte Corp | Composti di amminopirazindiolo come inibitori di pi3k-y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS |
| JP7746259B2 (ja) | 2019-12-20 | 2025-09-30 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性の化合物 |
| JP2021098692A (ja) | 2019-12-20 | 2021-07-01 | ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ | 核内受容体に対して活性の化合物 |
| US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60115411D1 (de) | 2000-04-12 | 2006-01-05 | Merck Frosst Canada & Co Kirkl | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten |
| AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| DOP2007000068A (es) * | 2006-04-12 | 2007-10-31 | Sanofi Aventis Us Llc | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 |
| WO2008039882A1 (en) * | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
-
2011
- 2011-03-15 EP EP11710373A patent/EP2547672A1/en not_active Withdrawn
- 2011-03-15 WO PCT/US2011/028427 patent/WO2011115940A1/en not_active Ceased
- 2011-03-15 CN CN2011800243826A patent/CN103038228A/zh active Pending
- 2011-03-15 CA CA2793223A patent/CA2793223A1/en not_active Abandoned
- 2011-03-15 AR ARP110100829A patent/AR080590A1/es unknown
- 2011-03-15 RU RU2012143897/04A patent/RU2012143897A/ru unknown
- 2011-03-15 MX MX2012010035A patent/MX2012010035A/es not_active Application Discontinuation
- 2011-03-15 KR KR1020127026848A patent/KR20130018770A/ko not_active Withdrawn
- 2011-03-15 SG SG2012063913A patent/SG183533A1/en unknown
- 2011-03-15 BR BR112012023178A patent/BR112012023178A2/pt not_active IP Right Cessation
- 2011-03-15 TW TW100108623A patent/TW201200133A/zh unknown
- 2011-03-15 JP JP2013500142A patent/JP2013522306A/ja not_active Withdrawn
- 2011-03-15 AU AU2011227417A patent/AU2011227417A1/en not_active Abandoned
- 2011-03-16 UY UY0001033278A patent/UY33278A/es not_active Application Discontinuation
-
2012
- 2012-09-11 US US13/610,027 patent/US20130005728A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012023178A2 (pt) | 2019-09-24 |
| RU2012143897A (ru) | 2014-04-27 |
| SG183533A1 (en) | 2012-10-30 |
| CA2793223A1 (en) | 2011-09-22 |
| UY33278A (es) | 2011-10-31 |
| CN103038228A (zh) | 2013-04-10 |
| EP2547672A1 (en) | 2013-01-23 |
| AU2011227417A1 (en) | 2012-10-11 |
| US20130005728A1 (en) | 2013-01-03 |
| KR20130018770A (ko) | 2013-02-25 |
| TW201200133A (en) | 2012-01-01 |
| WO2011115940A1 (en) | 2011-09-22 |
| JP2013522306A (ja) | 2013-06-13 |
| MX2012010035A (es) | 2012-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080590A1 (es) | Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2 | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
| BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
| AR074171A1 (es) | Derivados de pirazolopiridina, composicion farmaceutica que los comprende y su uso en el tratamiento de afecciones mediadas por pkctheta | |
| CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| BR112014010407A2 (pt) | compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel | |
| BR112014009717A2 (pt) | "derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica" | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| EA201290482A1 (ru) | Стабильные составы для лиофилизации терапевтических частиц | |
| BR112014015259A8 (pt) | composições compreendendo galatos e galamidas | |
| PE20141308A1 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| BR112015014701A2 (pt) | derivados de benzimidazol como inibidores de quinase | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| JO3073B1 (ar) | مثبطات ثنائية ملتحمة ثلاثية الحلقة ل cdk 4/6 و flt3 | |
| BRPI0617167B8 (pt) | sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação | |
| AR074089A1 (es) | Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2 | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| PE20140934A1 (es) | Derivados de pirazol | |
| BR112015008717A2 (pt) | composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii | |
| BR112013019160A2 (pt) | novos compostos, composição farmacêutica, uso, processos e métodos | |
| PE20091450A1 (es) | INHIBIDORES DE LA ESTEAROIL-CoA-DESATURASA | |
| BR112013026807A2 (pt) | derivados de metil amina bicíclicos substituídos como moduladores dos receptores de esfinfgosina-1 fosfato | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |